Comparison of vildagliptin and thiazolidinedione as add‐on therapy in patients inadequately controlled with metformin: results of the GALIANT trial – a primary care, type 2 diabetes study

Abstract

This short-term study suggests that vildagliptin is as effective as TZDs after 3-month treatment as an add-on to metformin in a primary care population that included diverse patient subgroups.